New drug combo shows promise in shrinking skin cancer before surgery
NCT ID NCT06288191
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can shrink or eliminate skin cancer in people with stage II to IV cutaneous squamous cell carcinoma. About 20 adults will receive the drugs for 6 weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have no cancer cells left in the removed tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy before surgery may cut skin cancer recurrence
- Scientists map metabolic shifts in skin cancer development
- Cancer-Killing virus shows promise in early trial for advanced tumors
- New drug IDP-001 takes on advanced cancers in early trial
- New combo therapy aims to shrink inoperable skin cancers
- Tiny needle patch takes aim at skin cancer